|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.08.26 - 01:21
|
Children′s Hospitals To Begin Offering Restorative Care For Detransitioners (ZeroHedge)
|
|
|
Children's Hospitals To Begin Offering Restorative Care For Detransitioners
Authored by Darlene McCormick Sanchez via The Epoch Times,
When Texas Children's Hospital's "detransition clinic" opens in Houston, it will become the first facility of its kind, giving patients who regret life-altering procedures a chance at restorative care.
Illustration by The Epoch Times, Zereshk/CC BY-SA 3.0
The facility, which has yet to announce an opening date, is part of an agreement with state and federal authorities to halt "gender-affirming care" at children's hospitals while offering help to those who transitioned medically.
A 10-page settlement term sheet, recently obtained by The Epoch Times through an open records request to the Texas attorney general's office, showed that services at the clinic will focus on multidisciplinary care.
Services are to include endocrinology, surgery, fertility counseling, psychiatry, psychotherapy, and speech pathology, among others.
In May and June...
|
|
|
|
|
03.08.26 - 18:12
|
Pharma-Fusion: Keine Traum-Hochzeit (FAZ)
|
|
|
Die Börse reagiert besorgt auf die Gerüchte um eine Fusion von Astra-Zeneca und BMS. Denn es stellt sich die Frage, was der Mehrwert für den britischen Konzern sein sollte....
|
|
|
|
|
03.08.26 - 16:54
|
Pharmakonzerne: Astra-Zeneca erwägt Megafusion (FAZ)
|
|
|
Der britische Pharmakonzern hat offenbar Gespräche über einen Zusammenschluss mit dem US-Wettbewerber Bristol Myers Squibb geführt. Ein solches Vorhaben würde wohl auf hohe kartellrechtliche Hürden stoßen....
|
|
|
03.08.26 - 15:12
|
$400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher" (ZeroHedge)
|
|
|
$400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
The Financial Times reported overnight that AstraZeneca has explored acquiring Bristol Myers Squibb in a potential megadeal that would create one of the world's largest drugmakers, with a combined market capitalization of nearly $400 billion.
The report cited people familiar with the matter, while both pharmaceutical giants declined to comment. Some Wall Street desks, however, are struggling to see the strategic rationale behind such a combination.
FT reported:
The companies have held discussions about a tie-up in recent months, according to people familiar with the matter. The talks could yield a deal in the near future but may be delayed or fall apart, the people said.
Bristol, valued at about $133 billion, would expand AstraZeneca's US presence but faces looming patent expirations for Eliquis and Opdivo, which together generate roughly half its sales. AstraZeneca, worth ab...
|
|
|
03.08.26 - 14:30
|
Chinese biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny (SCMP)
|
|
|
Wuxi AppTec, Asia's largest provider of contract pharmaceutical research, posted net income that smashed market expectations in the first half of the year amid strong demand tied to weight-loss and diabetes drugs, as well as gains in its US business.
Interim net profit attributable to the owners of the Shanghai-based drug contractor advanced 33.7 per cent to 11.08 billion yuan (US$1.64 billion) from a year earlier, surpassing a Bloomberg mean consensus estimate – drawn from a pool of 25 analysts......
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
